Numeco, an affiliate of Medytox, said on the 30th that it obtained marketing approval for the botulinum toxin product "NEWLUX" from Azerbaijan's Ministry of Health (MOH).
Azerbaijan is a country where the medical tourism market is growing rapidly around the capital, Baku, and demand for aesthetic procedures is increasing. Numeco plans to leverage the partnerships Medytox has built locally to ensure early market entry and expand the market share of "NEWLUX."
NEWLUX is a next-generation botulinum toxin product developed by Numeco. By applying the latest manufacturing processes, it improved Production yield and quality, and among 900-kilodalton (kDa) products, it is the first to use only non-animal media in the strain culture process, reducing the risk of contamination from animal-derived components. It also minimized chemical treatment steps to lower the possibility of denaturation of the active neurotoxin protein.
Medytox laid the groundwork for its local business by launching the botulinum toxin product "Meditoxin" (export name Qnox) in 2019 and four types of hyaluronic acid fillers "Neuramis" in 2020 in Azerbaijan.
Building on this approval, Numeco plans to continue seeking marketing approvals in neighboring countries of Azerbaijan to expand overseas distribution channels.
Starting with Peru in 2024, NEWLUX is expanding its entry into countries in Latin America, Asia, and Europe, including Thailand, Georgia, Bolivia, Moldova, the Dominican Republic, El Salvador, and Ukraine.
A Numeco official said, "With this approval, we have secured a strategic foothold for entry into neighboring countries," and added, "We will increase NEWLUX's global market share by strengthening local partnerships and implementing country-specific strategies."